Phio Pharmaceuticals (NASDAQ:PHIO) Director Purchases $17,100.00 in Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Todd Plott purchased 15,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were purchased at an average cost of $1.14 per share, with a total value of $17,100.00. Following the completion of the purchase, the director owned 15,000 shares in the company, valued at $17,100. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phio Pharmaceuticals Stock Performance

Shares of PHIO stock opened at $1.18 on Friday. Phio Pharmaceuticals Corp. has a 1 year low of $0.81 and a 1 year high of $4.19. The business’s fifty day moving average is $1.04 and its 200-day moving average is $1.12. The stock has a market cap of $13.71 million, a PE ratio of -0.91 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, meeting the consensus estimate of ($0.36). Equities research analysts predict that Phio Pharmaceuticals Corp. will post -1.41 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC grew its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 92,638 shares of the company’s stock after acquiring an additional 34,732 shares during the period. Geode Capital Management LLC owned about 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.31% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical?stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next?generation RNAi compounds with potential applications in oncology and immuno?oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double?stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.